Meissa Vaccines is a biotechnology company focused on advancement of unmet vaccines against viruses that cause serious human diseases, including respiratory syncytial virus (RSV) and SARS-CoV-2, the novel coronavirus that causes COVID-19. Our innovative platform technology for viral genetic engineering can be applied to multiple pathogens.
Our passion is child health, but our vaccine programs have the potential to benefit multiple age and population groups. Successful vaccines for RSV and related viruses will have widespread benefits for society and families. These include alleviating the burden of serious lower respiratory tract disease and reducing asthma and COPD exacerbations.